Randomised controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine
Journal of Clinical Investigation,
Год журнала:
2024,
Номер
134(17)
Опубликована: Июль 11, 2024
BACKGROUNDThere
is
uncertainty
about
the
timing
of
booster
vaccination
against
COVID-19
in
highly
vaccinated
populations
during
present
endemic
phase
COVID-19.
Studies
focused
on
primary
have
previously
suggested
improved
immunity
with
a
longer
interval
between
first
and
second
vaccine
doses.METHODSWe
conducted
randomized,
controlled
trial
(November
2022-August
2023)
assigned
52
fully
adults
to
an
immediate
or
3-month
delayed
bivalent
Spikevax
mRNA
vaccine.
Follow-up
visits
were
completed
for
48
participants
(n
=
24
per
arm),
collection
saliva
plasma
samples
following
each
visit.RESULTSThe
rise
neutralizing
antibody
responses
ancestral
Omicron
strains
almost
identical
arms.
Analyses
salivary
(IgG,
IgA),
antibody-dependent
phagocytic
activity,
decay
kinetics
similar
2
Symptomatic
asymptomatic
SARS-CoV-2
infections
occurred
49%
(21
49)
over
median
11.5
months
follow-up
also
arms.CONCLUSIONSOur
data
suggest
that
there
was
no
benefit
delaying
preimmune
COVID-19.TRIAL
REGISTRATIONAustralian
New
Zealand
Clinical
Trials
Registry
number
12622000411741
(https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000411741).FUNDINGNational
Health
Medical
Research
Council,
Australia
(program
grant
App1149990)
Future
Fund
(App2005544).
Язык: Английский
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Immunity & Ageing,
Год журнала:
2025,
Номер
22(1)
Опубликована: Янв. 2, 2025
As
older
age
and
having
certain
comorbidities
can
influence
humoral
responses
to
vaccination,
we
studied
antibody
after
the
COVID-19
booster
campaigns
in
nursing
home
(NH)
residents.
In
a
two
year
longitudinal
study
with
Dutch
NH
residents
(n
=
107),
aged
50
years
over,
monitored
serum
prior
vaccination
third,
fourth
BNT162b2
(wild-type;
WT),
bivalent
(WT/OMI
BA.1)
fifth
vaccine.
Data
on
vaccinations,
infections,
comorbidities,
and,
for
some
participants,
clinical
symptoms
infection
were
obtained
questionnaires.
compared
of
BNT162b2-vaccinated,
healthier
community-dwelling
adults
32)
from
general
population.
The
vaccinations
substantially
increased
anti-WT
anti-Omicron
SARS-CoV-2
Spike
S1
(S1)
protein
receptor
binding
domain
(RBD)-antibody
concentrations
This
resulted
comparable
levels
between
infection-naïve
infected
residents,
decline
treatment
duration
symptom
severity
SARS-CoV-2-infected
Between
one
twelve
months
dose,
BA.1
waned
faster
than
those
against
WT
strain.
upheld
Omicron
SARS-CoV-2.
This,
addition
less
virulent
circulating
strains,
decreased
durations
Boosting
this
vulnerable
group
should,
therefore,
be
continued
prevent
waning
immunity
achieve
sufficient
protection
especially
newly
emerging
variants
concern.
Язык: Английский
No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations
Nature Communications,
Год журнала:
2025,
Номер
16(1)
Опубликована: Июнь 5, 2025
Язык: Английский
Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study
The Journal of Infectious Diseases,
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 7, 2024
Abstract
Background
Bivalent
messenger
RNA
(mRNA)
vaccines,
designed
to
combat
emerging
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
variants,
incorporate
ancestral
strains
and
a
new
variant.
Our
study
assessed
the
immune
response
in
previously
vaccinated
individuals
of
Swiss
HIV
Cohort
Study
(SHCS)
Transplant
(STCS)
following
bivalent
mRNA
vaccination.
Methods
Eligible
SHCS
STCS
participants
received
approved
SARS-CoV-2
vaccines
(mRNA-1273.214
or
BA.1-adapted
BNT162b2)
within
clinical
routine.
Blood
samples
were
collected
at
baseline,
4
weeks,
8
6
months
postvaccination.
We
analyzed
proportion
with
anti-spike
protein
antibody
≥1642
units/mL
(indicating
protection
against
infection),
subsample
T-cell
(including
mean
concentrations),
stratifying
results
by
cohorts
population
characteristics.
Results
In
participants,
baseline
concentrations
observed
87%
(96/112),
reaching
nearly
100%
follow-ups.
Among
58%
(35/60)
had
antibodies
units/mL,
increasing
80%
months.
Except
for
lung
transplant
recipients,
all
showed
5-fold
increase
geometric
weeks
reduction
half
At
responses
positive
96%
(26/27)
36%
(16/45)
(moderate
53%
months).
Few
reported
infections,
side-effects,
serious
adverse
events.
Conclusions
vaccination
elicited
robust
humoral
human
immunodeficiency
virus
(HIV)
solid
organ
transplants,
delayed
recipients.
Despite
waning
effect,
levels
remained
high
events
rare.
Clinical
Trials
Registration
.
NCT04805125.
Язык: Английский
Effectiveness of bivalent mRNA booster vaccination and previous infection in older adults during Omicron period: real-world evidence
Age and Ageing,
Год журнала:
2024,
Номер
53(11)
Опубликована: Ноя. 1, 2024
Abstract
Background
The
effectiveness
of
booster
bivalent
vaccines
against
the
Omicron
variant,
particularly
amongst
older
patients,
remains
uncertain.
Objective
We
sought
to
compare
relative
a
fourth
dose
vaccine
using
messenger
ribonucleic
acid
(mRNA),
by
comparing
patients
who
had
and
not
received
this
dose.
Methods
conducted
matched
retrospective
cohort
study
assess
risk
COVID-19
infection,
hospitalization
death
people
aged
>60
years
with
four
doses
as
compared
those
only
three
doses.
Cox
proportional
hazard
regression
models
were
used
estimate
adjusted
ratios
(HRs)
95%
confidence
intervals
(CIs).
age,
sex,
nursing-home,
comorbidities,
primary
care
setting
previous
episodes
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infections.
also
investigated
impact
prior
SARS-CoV-2
infection
within
each
cohort,
same
methodology.
Results
administration
mRNA
conferred
significant
additional
protection
(HR:
0.479;
CI:
0.454–0.506),
0.393;
0.348–0.443)
30-day
mortality
0.234;
0.171–0.318),
individuals
third
monovalent
In
both
cohorts,
history
involves
lower
COVID-infection,
death.
Conclusions
During
period
predominance,
receiving
dose,
vaccine,
provides
extra
mortality.
Antecedents
vaccination
notable
reduction
in
above
outcomes.
Язык: Английский
No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 27, 2024
Abstract
Frequent
SARS-CoV-2
vaccination
in
vulnerable
populations
has
raised
concerns
that
this
may
contribute
to
T
cell
exhaustion,
which
could
negatively
affect
the
quality
of
immune
protection.
Herein,
we
examined
impact
repeated
on
phenotypic
and
functional
exhaustion
frail
older
adults
long-term
care,
individuals
immunosuppressive
drugs,
healthy
adults.
Spike-specific
CD4
+
CD8
+
levels
did
not
decline
any
cohort
following
vaccination,
nor
expression
markers
spike-specific
or
total
cells
increase.
production
multiple
cytokines
(i.e.
polyfunctionality)
response
spike
protein
vaccination.
None
cohorts
displayed
elevated
terminally
differentiated
vaccinations.
Thus,
was
associated
with
increased
adults,
immunosuppressed
individuals,
Язык: Английский